New drug ALN-AGT01 RVR tested for safety in healthy people
NCT ID NCT06675565
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested the safety and tolerability of a single dose of ALN-AGT01 RVR in 42 healthy adults. Participants received either the drug or a placebo by injection. The study is complete and focused on side effects and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ALN-AGT01 RVR
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Trial Site
Montreal, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults